Responses
Clinical and epidemiological research
Extended report
Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases
Compose a Response to This Article
Other responses
Jump to comment:
- Published on: 13 April 2016
- Published on: 13 April 2016Azathioprine: An explanation for the risk of skin SCC among patients with Crohn’s disease?Show More
Dear editor
We read with interest the recent metaanalysis by Burmester et al1 on the spectrum of adverse events that were recorded among the participants of global adalimumab clinical trials. However, the observed increased risk of Crohn’s disease (CD) patients to develop a skin squamous cell carcinoma (SCC) compared to base-line and to other adalimumab-treated patients is quite important to deserve an additional comment...
Conflict of Interest:
None declared.